DDX5 enhances HIF-1 activity by promoting the interaction of HIF-1 with HIF-1 and recruiting the resulting heterodimer to its target gene loci

Background InformationCancer cells acquire malignant characteristics and therapy resistance by employing the hypoxia-inducible factor 1 (HIF-1)-dependent adaptive response to hypoxic microenvironment in solid tumors. Since the underlying molecular mechanisms remain unclear, difficulties are associated with establishing effective therapeutic strategies.ResultsWe herein identified DEAD-box helicase 5 (DDX5) as a novel activator of HIF-1 and found that it enhanced the heterodimer formation of HIF-1 alpha and HIF-1 beta and facilitated the recruitment of the resulting HIF-1 to its recognition sequence, hypoxia-response element (HRE), leading to the expression of a subset of cancer-related genes under hypoxia.ConclusionsThis study reveals that the regulation of HIF-1 recruitment to HRE is an important regulatory step in the control of HIF-1 activity.SignificanceThe present study provides novel insights for the development of strategies to inhibit the HIF-1-dependent expression of cancer-related genes. Cancer cells become malignant and acquire resistance to therapy by activating hypoxia-inducible factor 1 (HIF-1), but the underlying mechanism is not fully understood. Shirai et al. identified DEAD-box helicase 5 (DDX5) as a novel activator of HIF-1 and found that it enhances the interaction of HIF-1 alpha with HIF-1 beta, facilitates the recruitment of the resulting heterodimer to its recognition sequence, HRE, and induces the expression of a subset of cancer-related genes under hypoxia.image